SU1165223A3 - Способ получени эргоалкалоидов - Google Patents
Способ получени эргоалкалоидов Download PDFInfo
- Publication number
- SU1165223A3 SU1165223A3 SU762412401A SU2412401A SU1165223A3 SU 1165223 A3 SU1165223 A3 SU 1165223A3 SU 762412401 A SU762412401 A SU 762412401A SU 2412401 A SU2412401 A SU 2412401A SU 1165223 A3 SU1165223 A3 SU 1165223A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- ergoalkaloids
- methanesulfonate
- mixture
- fact
- flask
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 7
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical class C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 claims description 3
- 229960002032 dihydroergocryptine Drugs 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 claims 1
- 229960004318 dihydroergocristine Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000011343 solid material Substances 0.000 abstract 2
- 229930015720 peptide alkaloid Natural products 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000654 additive Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 1
- UOOWRCRLTSXSAV-GSZJWLEYSA-N dihydroergocornine mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 UOOWRCRLTSXSAV-GSZJWLEYSA-N 0.000 description 1
- SPXACGZWWVIDGR-SPZWACKZSA-N dihydroergocristine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 SPXACGZWWVIDGR-SPZWACKZSA-N 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2546577A DE2546577B2 (de) | 1975-10-17 | 1975-10-17 | Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1165223A3 true SU1165223A3 (ru) | 1985-06-30 |
Family
ID=5959411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU762412401A SU1165223A3 (ru) | 1975-10-17 | 1976-10-15 | Способ получени эргоалкалоидов |
Country Status (28)
| Country | Link |
|---|---|
| JP (1) | JPS5854122B2 (enExample) |
| AT (1) | AT362510B (enExample) |
| AU (1) | AU508628B2 (enExample) |
| BE (1) | BE847368A (enExample) |
| CA (1) | CA1079641A (enExample) |
| CH (1) | CH643737A5 (enExample) |
| CS (1) | CS199647B2 (enExample) |
| DE (1) | DE2546577B2 (enExample) |
| DK (1) | DK146194C (enExample) |
| ES (1) | ES452420A1 (enExample) |
| FI (1) | FI762875A7 (enExample) |
| FR (1) | FR2327764A1 (enExample) |
| GB (1) | GB1560406A (enExample) |
| GR (1) | GR61268B (enExample) |
| HK (1) | HK3183A (enExample) |
| HU (1) | HU172533B (enExample) |
| IE (1) | IE43778B1 (enExample) |
| IL (1) | IL50686A (enExample) |
| MY (1) | MY8400063A (enExample) |
| NL (1) | NL184558C (enExample) |
| NO (1) | NO144468C (enExample) |
| NZ (1) | NZ182341A (enExample) |
| PH (1) | PH14513A (enExample) |
| PT (1) | PT65719B (enExample) |
| SE (1) | SE430379B (enExample) |
| SG (1) | SG63082G (enExample) |
| SU (1) | SU1165223A3 (enExample) |
| ZA (1) | ZA766166B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| WO1980001242A1 (fr) * | 1978-12-21 | 1980-06-26 | Sandoz Ag | Preparations galeniques |
| US4411882A (en) | 1978-12-21 | 1983-10-25 | Sandoz Ltd. | Galenical compositions |
| FR2454804B1 (fr) * | 1979-04-26 | 1986-11-21 | Sanofi Sa | Medicament a base de dihydroergotoxine et son procede de preparation |
| US4366145A (en) * | 1981-06-24 | 1982-12-28 | Sandoz, Inc. | Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation |
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| NL194389C (nl) * | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
| ES2039287T3 (es) * | 1987-01-14 | 1993-09-16 | Ciba-Geigy Ag | Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles. |
| FR2610827B1 (fr) * | 1987-02-18 | 1991-09-13 | Pf Medicament | Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication |
| US5064656A (en) * | 1989-11-14 | 1991-11-12 | Dr. Gergely & Co. | Uncoated pharmaceutical reaction tablet |
| DE4401646A1 (de) * | 1994-01-21 | 1995-07-27 | Krewel Werke Gmbh | Optimal freisetzende Kava-Extrakte |
| US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| AU761994C (en) * | 1997-12-22 | 2004-01-08 | Merck Sharp & Dohme Corp. | Molecular dispersion composition with enhanced bioavailability |
| US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
| US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| US7771746B2 (en) | 1999-12-03 | 2010-08-10 | Polichem Sa | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| EP1512403A1 (en) * | 1999-12-03 | 2005-03-09 | Polichem S.A. | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| US7135436B2 (en) | 2003-05-05 | 2006-11-14 | J.F. Daley International, Ltd. | Solid algicide, preparation and usage in recirculating water |
| DE60309356T2 (de) * | 2003-06-27 | 2007-08-30 | Bioprogress S.P.A. | Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich |
| WO2016198983A1 (en) | 2015-06-09 | 2016-12-15 | Bend Research Inc. | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| KR102882996B1 (ko) * | 2025-04-07 | 2025-11-07 | (주)휴마스 | 액체크로마토그래피와 막전도도 측정모듈 및 개량된 uv산화반응기를 이용하는 분획된 수중 탄소 및 질소 측정장치 및 이를 이용한 측정방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1175430A (en) * | 1966-04-07 | 1969-12-23 | Sandoz Ltd | Pharmaceutical Compositions containing Ergot Alkaloids |
-
1975
- 1975-10-17 DE DE2546577A patent/DE2546577B2/de not_active Withdrawn
-
1976
- 1976-10-01 CH CH1244876A patent/CH643737A5/de not_active IP Right Cessation
- 1976-10-08 NO NO763446A patent/NO144468C/no unknown
- 1976-10-08 FI FI762875A patent/FI762875A7/fi not_active Application Discontinuation
- 1976-10-08 DK DK454176A patent/DK146194C/da not_active IP Right Cessation
- 1976-10-08 SE SE7611189A patent/SE430379B/xx not_active IP Right Cessation
- 1976-10-13 NL NLAANVRAGE7611295,A patent/NL184558C/xx not_active IP Right Cessation
- 1976-10-14 PH PH19008A patent/PH14513A/en unknown
- 1976-10-14 FR FR7630866A patent/FR2327764A1/fr active Granted
- 1976-10-14 CA CA263,423A patent/CA1079641A/en not_active Expired
- 1976-10-15 CS CS766685A patent/CS199647B2/cs unknown
- 1976-10-15 NZ NZ182341A patent/NZ182341A/xx unknown
- 1976-10-15 AU AU18754/76A patent/AU508628B2/en not_active Expired
- 1976-10-15 AT AT767976A patent/AT362510B/de not_active IP Right Cessation
- 1976-10-15 SU SU762412401A patent/SU1165223A3/ru active
- 1976-10-15 ES ES452420A patent/ES452420A1/es not_active Expired
- 1976-10-15 GB GB42907/76A patent/GB1560406A/en not_active Expired
- 1976-10-15 PT PT65719A patent/PT65719B/pt unknown
- 1976-10-15 ZA ZA00766166A patent/ZA766166B/xx unknown
- 1976-10-15 BE BE171578A patent/BE847368A/xx not_active IP Right Cessation
- 1976-10-15 IL IL50686A patent/IL50686A/xx unknown
- 1976-10-15 IE IE2282/76A patent/IE43778B1/en not_active IP Right Cessation
- 1976-10-15 HU HU76SA00002985A patent/HU172533B/hu not_active IP Right Cessation
- 1976-10-16 GR GR51952A patent/GR61268B/el unknown
- 1976-10-16 JP JP51123463A patent/JPS5854122B2/ja not_active Expired
-
1982
- 1982-12-23 SG SG630/82A patent/SG63082G/en unknown
-
1983
- 1983-01-20 HK HK31/83A patent/HK3183A/xx unknown
-
1984
- 1984-12-30 MY MY63/84A patent/MY8400063A/xx unknown
Non-Patent Citations (1)
| Title |
|---|
| Патент US 3146169, кл. 424-15, 1962. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1165223A3 (ru) | Способ получени эргоалкалоидов | |
| KR950006710B1 (ko) | 암로디핀의 베실레이트염의 제조방법 | |
| KR100664560B1 (ko) | Ｌ(-)-카르니틴의 비흡습성 염을 제조하는 신규한 방법 | |
| US8796451B2 (en) | Crystalline pharmaceutical | |
| RU2002745C1 (ru) | Способ получени кристаллов дигидрата гидрохлорида ондансетрона уменьшенного размера | |
| EP0265226B1 (en) | Spray dried acetaminophen | |
| GB2062467A (en) | Aqueous solution of nitroglycerin | |
| AU7723894A (en) | Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof | |
| NZ242191A (en) | Crystalline tiagabine hydrochloride monohydrate, preparation and pharmaceutical compositions thereof | |
| CN111406056A (zh) | 4-(4-(1-异丙基-7-氧代-1,4,6,7-四氢螺[吲唑-5,4’-哌啶]-1’-羰基)-6-甲氧基吡啶-2-基)苯甲酸的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐 | |
| FI70138C (fi) | Foerfarande foer framstaellning av en foerbaettrad injekterbarloesning innehaollande kalcium/magnesium/oxitetracyklinsa mklat | |
| CN118598799A (zh) | 一种门冬氨酸左旋氨氯地平原料药、片剂及制备方法 | |
| AU2001250920B2 (en) | Crystalline pharmaceutical | |
| US4222939A (en) | Process for preparing solid sodium amoxycillin | |
| AU2001250920A1 (en) | Crystalline pharmaceutical | |
| SU1053748A3 (ru) | Способ получени тетрагидро 2 @ бензо-/ @ /-пиррола | |
| WO2004011432A1 (en) | Organic acid salt of amlodipine | |
| KR950007228B1 (ko) | 암로디핀의 베실레이트염 | |
| RU2042686C1 (ru) | Кристаллический этопозид 4`-фосфат диэтанолсольват и способ его получения | |
| SU648101A3 (ru) | Способ получени стабильной полиморфной формы 1-окси-3-(1,1-диметилгептил)-6,6-диметил-6,6а,7,8,10,10агексагидро-9н-дибензо (в, ) пиран9-она | |
| EP0012496A1 (en) | A process for the preparation of a solid sodium amoxycillin and aqueous solutions thereof | |
| SU537070A1 (ru) | Диметилбензосульфонат кускгигрина в качестве ганглиоблокатора кратковременного действи | |
| EP2880040A1 (en) | Bortezomib esters and formulations thereof | |
| ZA200206962B (en) | Crystalline pharmaceutical. | |
| SI9011607A (sl) | Postopek za pripravo čiste oblike polimorfne modifikacije b cimetidina in mešanic polimorfne modifikacije a cimetidina in polimorfne modifikacije b cimetidina v poljubnem razmerju komponent |